{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:48:58Z","timestamp":1792057738383,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.xops.2026.101346","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:59:54Z","timestamp":1785826794000},"page":"101346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The TITAN Study: Topical Infliximab for the Treatment of Advanced Corneal Melt and Ocular Surface Inflammation"],"prefix":"10.1016","volume":"6","author":[{"given":"Soumaya","family":"Bouhout","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Geoffrion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bostan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9534-090X","authenticated-orcid":false,"given":"Marie-Claude","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2026.101346_bib1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/00003226-200009000-00008","article-title":"Twenty-five-year panorama of corneal immunology: emerging concepts in the immunopathogenesis of microbial keratitis, peripheral ulcerative keratitis, and corneal transplant rejection","volume":"19","author":"Dana","year":"2000","journal-title":"Cornea"},{"key":"10.1016\/j.xops.2026.101346_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152269","article-title":"Biologics in peripheral ulcerative keratitis","volume":"63","author":"Clarke","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.xops.2026.101346_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0896-1549(01)00017-7","article-title":"Mechanisms of corneal ulceration","volume":"15","author":"Ma","year":"2002","journal-title":"Ophthalmol Clin North Am"},{"key":"10.1016\/j.xops.2026.101346_bib4","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1007\/PL00007449","article-title":"Proteolytic mechanisms in corneal ulceration and repair","volume":"290 suppl","author":"Fini","year":"1998","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.xops.2026.101346_bib5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2147\/OPTH.S157430","article-title":"Recurrent corneal erosion: a comprehensive review","volume":"13","author":"Miller","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.xops.2026.101346_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.clae.2025.102438","article-title":"How effective and safe are punctal plugs in treating dry eye disease? A systematic review and meta-analysis","volume":"48","author":"Chen","year":"2025","journal-title":"Contact Lens and Anterior Eye"},{"key":"10.1016\/j.xops.2026.101346_bib7","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s004170050118","article-title":"Effect of 0.1% dexamethasone on epithelial healing in experimental corneal alkali wounds: morphological changes during the repair process","volume":"236","author":"Chung","year":"1998","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.xops.2026.101346_bib8","first-page":"69","article-title":"Corneal melt as a complication of a peripheral ulcerative keratitis in a patient with rheumatoid arthritis","volume":"28","author":"Mesa Navas","year":"2021","journal-title":"Rev Colomb Reumatol (Eng Ed)"},{"key":"10.1016\/j.xops.2026.101346_bib9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/jcto2040011","article-title":"Updates on systemic immunomodulation in peripheral ulcerative keratitis","volume":"2","author":"Maleki","year":"2024","journal-title":"J Clin Transl Ophthalmol"},{"key":"10.1016\/j.xops.2026.101346_bib10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/08820538.2021.1966059","article-title":"Systemic immunosuppression in cornea and ocular surface disorders: a ready reckoner for ophthalmologists","volume":"37","author":"Kate","year":"2022","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.xops.2026.101346_bib11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/01.rhu.0000249766.24780.95","article-title":"Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab","volume":"12","author":"Atchia","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.xops.2026.101346_bib12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ajo.2011.01.059","article-title":"Use of infliximab in the treatment of peripheral ulcerative keratitis in Crohn disease","volume":"152","author":"Pham","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101346_bib13","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/01.ico.0000154391.28254.1d","article-title":"Therapy of progressive rheumatoid arthritis-associated corneal ulceration with infliximab","volume":"24","author":"Thomas","year":"2005","journal-title":"Cornea"},{"key":"10.1016\/j.xops.2026.101346_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/ICO.0b013e318181a84f","article-title":"Infliximab for the treatment of refractory progressive sterile peripheral ulcerative keratitis associated with late corneal perforation: 3-year follow-up","volume":"28","author":"Odorcic","year":"2009","journal-title":"Cornea"},{"key":"10.1016\/j.xops.2026.101346_bib15","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/ibd.21358","article-title":"Infliximab for severe peripheral ulcerative keratopathy revealing Crohn's disease","volume":"17","author":"Angioi","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.xops.2026.101346_bib16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s10384-010-0889-7","article-title":"Infliximab for progressive peripheral ulcerative keratitis in a patient with juvenile rheumatoid arthritis","volume":"55","author":"Oh","year":"2011","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101346_bib17","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ajo.2011.11.006","article-title":"Use of infliximab in the treatment of peripheral ulcerative keratitis in crohn disease","volume":"153","author":"Singh","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101346_bib18","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.xops.2026.101346_bib19","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1167\/iovs.12-10782","article-title":"Safety and efficacy of topical infliximab in a mouse model of ocular surface scarring","volume":"54","author":"Ferrari","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"suppl 1","key":"10.1016\/j.xops.2026.101346_bib20","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1097\/ICO.0b013e31826a80ea","article-title":"Effectiveness of topical infliximab in a mouse model of experimental dry eye","volume":"31","author":"Li","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.xops.2026.101346_bib21","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/ICO.0b013e318271cc2a","article-title":"The effect of topical infliximab on corneal neovascularization in rabbits","volume":"32","author":"Kim","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.xops.2026.101346_bib22","first-page":"418","article-title":"Stability and in vitro toxicity of an infliximab eye drop formulation","volume":"18","author":"Robert","year":"2014","journal-title":"Int J Pharm Compd"},{"key":"10.1016\/j.xops.2026.101346_bib23","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the ocular surface disease index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2026.101346_bib24","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jtos.2020.02.007","article-title":"Association between dry eye and depressive symptoms: Large-scale crowdsourced research using the DryEyeRhythm iPhone application","volume":"18","author":"Inomata","year":"2020","journal-title":"Ocul Surf"},{"key":"10.1016\/j.xops.2026.101346_bib25","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.4103\/jfmpc.jfmpc_831_21","article-title":"Agreement between WHO-UMC causality scale and the Naranjo algorithm for causality assessment of adverse drug reactions","volume":"10","author":"Shukla","year":"2021","journal-title":"J Fam Med Prim Care"},{"key":"10.1016\/j.xops.2026.101346_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12247601","article-title":"Beauveria bassiana Keratitis: a case series and review of literature","volume":"12","author":"Knutsson","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.xops.2026.101346_bib28","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/ecco-jcc\/jjae059","article-title":"Intravenous versus subcutaneous infliximab in inflammatory bowel disease: a systematic review and meta-analysis","volume":"18","author":"Chetwood","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.xops.2026.101346_bib29","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1111\/apt.18000","article-title":"Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease","volume":"59","author":"Vuijk","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.xops.2026.101346_bib30","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S2468-1253(24)00200-0","article-title":"Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial","volume":"9","author":"Choy","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.xops.2026.101346_bib31","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1053\/j.gastro.2024.07.046","article-title":"Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative colitis: 2024 American Gastroenterological Association evidence synthesis","volume":"167","author":"Ananthakrishnan","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.xops.2026.101346_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2024.214093","article-title":"A macromolecule infliximab loaded reverse nanomicelles-based transdermal hydrogel: an innovative approach against rheumatoid arthritis","volume":"167","author":"Khan","year":"2025","journal-title":"Biomater Adv"},{"key":"10.1016\/j.xops.2026.101346_bib33","article-title":"The use of TNF-\u03b1 inhibitors in active ankylosing spondylitis treatment","volume":"16","author":"Zouris","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.xops.2026.101346_bib34","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/ard-2024-225534","article-title":"Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"83","author":"Kerschbaumer","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.xops.2026.101346_bib35","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00403-024-03398-y","article-title":"Short term efficacy of biological treatment for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis","volume":"316","author":"Ismail","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.xops.2026.101346_bib36","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/ICO.0000000000003738","article-title":"TNF-\u03b1 suppression attenuates limbal stem cell damage in ocular injury","volume":"44","author":"Zhou","year":"2024","journal-title":"Cornea"},{"key":"10.1016\/j.xops.2026.101346_bib37","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/ICL.0000000000000770","article-title":"TNF-\u03b1 inhibitors for the management of intractable corneal melt: report of three cases and review of the literature","volume":"47","author":"Utine","year":"2021","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.xops.2026.101346_bib38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5693\/djo.01.2009.002","article-title":"Boston Keratoprosthesis in Stevens-Johnson syndrome: a case of using infliximab to prevent tissue necrosis","volume":"15","author":"Dohlman","year":"2009","journal-title":"Digit J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101346_bib39","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s10620-018-5319-6","article-title":"Incidence and management of infusion reactions to infliximab in an alternate care setting","volume":"64","author":"Checkley","year":"2019","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.xops.2026.101346_bib40","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1111\/aos.15786","article-title":"The prophylactic value of TNF-\u03b1 inhibitors against retinal cell apoptosis and optic nerve axon loss after corneal surgery or trauma","volume":"102","author":"Paschalis","year":"2024","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.xops.2026.101346_bib41","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1001\/archopht.118.12.1666","article-title":"Topical soluble tumor necrosis factor receptor type I suppresses ocular chemokine gene expression and rejection of allogeneic corneal transplants","volume":"118","author":"Qian","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2026.101346_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11061757","article-title":"Efficacy of early optimization of infliximab guided by therapeutic drug monitoring during induction\u2014a prospective trial","volume":"11","author":"Garcia","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.xops.2026.101346_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.MIB.0000436951.80898.6d","article-title":"Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"O'Meara","year":"2014","journal-title":"Inflamm Bowel Dis"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526002848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526002848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:25:14Z","timestamp":1792056314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914526002848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666914526002848"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2026.101346","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The TITAN Study: Topical Infliximab for the Treatment of Advanced Corneal Melt and Ocular Surface Inflammation","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2026.101346","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101346"}}